SCHEMBL30096604

SCHEMBL30096604

Cn1nc(-c2cc(C(F)(F)F)n(-c3ccc(NC(=O)c4ccccc4Cl)nc3)n2)oc1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.51
ALOX5 P09917 1/20 0.44
TBXAS1 P24557 1/20 0.44
SLC6A3 Q01959 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.40
RAB9A P51151 3/20 0.40
TP53 P04637 2/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 2/20 0.39
RPS6KA3 P51812 1/20 0.39
IL2 P60568 1/20 0.39
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
PTBP1 P26599 1/20 0.38
GRM5 P41594 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15529721 1.00 EPHX2 (0.51) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL15529498 0.91 EPHX2 (0.51) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL30096615 0.91 EPHX2 (0.51) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL16650186 0.91 EPHX2 (0.51) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL30096551 0.91 EPHX2 (0.51) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL18143557 0.88 EPHX2 (0.65) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL15529662 0.88 IL2 (0.49) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL30096565 0.88 IL2 (0.49) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL16650514 0.88 EPHX2 (0.48) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1
SCHEMBL15529085 0.88 EPHX2 (0.48) EPHX2ALOX5TBXAS1SLC6A3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS AVENUE CAPITAL MANAGEMENT II, L.P. 2025-04-17 US disclosed
EP-4465988-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS Calcimedica, Inc. (US) 2024-11-27 EP disclosed
CN-118871110-A Methods and compositions for treating inflammatory lesions of the lung 钙医学公司 2024-10-29 CN disclosed
WO-2023141523-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS CALCIMEDICA, INC. (US) 2023-07-27 WO disclosed
CN-115835878-A Methods and compositions for treating acute lung injury and acute respiratory distress syndrome 钙医学公司 2023-03-21 CN disclosed
EP-4121089-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME Calcimedica, Inc. (US) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120969-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS IL1B, MAVS, MMP8 EPHX2 2452/4885ALOX5 682/4885TBXAS1 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.